- Home
- News
- canada alberta
- genomic data
Refine by
Genomic Data Articles & Analysis
49 news found
BC Platforms has embedded NVIDIA accelerated computing into BC Mosaic, its trusted research environment, enabling faster GPU-powered analytics and AI-led analyses across clinical, multi-omics, and real-world data to support precision medicine and accelerated drug development.NVIDIA integration in BC MosaicNVIDIA technology is now natively available within BC Mosaic, providing direct, ...
BC Platforms today announced enhancements to BC Mosaic, its AI-powered trusted research environment (TRE), now available on AWS Marketplace. The update delivers an all-new user interface and enables secure, compliant analysis of complex clinical, real-world, and multi-omics data within a single TRE, simplifying deployment, configuration, and lifecycle management.BC Mosaic is designed to ...
SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a global leader in data-driven medicine, today announced it has successfully achieved ISO/IEC 27017:2015 and ISO/IEC 27018:2019 certifications for information security and privacy protection in its cloud services from BSI, the business improvement and standards company. It has also achieved recertification to ISO/IEC ...
SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a leader in data-driven medicine, announced today that Tennessee Oncology, one of the United States’ largest community-based cancer care specialists that treats nearly half of Tennessee’s cancer patients across 35 clinics, has expanded its relationship with SOPHiA GENETICS to advance its cancer research. ...
SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology leader in data-driven medicine, today announced the next step in the partnership between the Company and Genomenon, a leading genomic intelligence company, to support better, data-driven outcomes in the rare disease and oncology fields. The two companies have expanded the integration of Genomenon’s Mastermind® Genomic ...
SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a leader in data-driven medicine, will unveil new research at the European Society for Medical Oncology (ESMO) 2024. The study, conducted in collaboration with AstraZeneca, leverages advanced AI-driven techniques to identify subgroups of stage IV non-small cell lung cancer (NSCLC) patients who could most benefit from ...
SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a global leader in data-driven medicine, today announced a new milestone in the global introduction of the liquid biopsy test MSK-ACCESS® powered with SOPHiA DDM™, first announced in October 2023. Under a definitive partnership agreement with AstraZeneca (LSE/STO/Nasdaq: AZN), SOPHiA GENETICS will ...
SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a global leader in data-driven medicine, today announced that the company is joining the European Liquid Biopsy Society (ELBS), a prestigious network consisting of partners from academia and industry with the common goal of making liquid biopsy tests part of the routine standard of care. SOPHiA GENETICS offers a ...
SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a global leader in data-driven medicine, today announced an update from the Company’s work with biopharma company Boundless Bio. SOPHiA GENETICS first partnered with Boundless Bio in 2022 to develop and deploy Boundless Bio’s extrachromosomal DNA (ecDNA) detection algorithm as a clinical trial device, to ...
SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a global leader in data-driven medicine, today launched the new generation of the SOPHiA DDM™ Platform. The new-gen SOPHiA DDM™ Platform offers a new architecture designed to more efficiently compute large amounts of data at-scale, while elevating customer experience with integrated access to multimodal ...
CD Genomics, a pioneering leader in genomic solutions, is proud to announce its cutting-edge whole genome sequencing (WGS) services. Utilizing the latest technologies from Illumina and PacBio platforms, CD Genomics offers precise and affordable sequencing solutions for a wide range of organisms, including viruses, microbes, plants, animals, and humans. Whole genome sequencing represents a ...
CD Genomics, a prominent leader in the next generation sequencing arena, proudly announce the launch of a groundbreaking 5mC/5hmC sequencing service. This innovative service is poised to empower researchers by providing a deeper insight into epigenetic variations, unlocking the mysteries of epigenetics, and catalyzing pivotal advancements in the realm of life science research and precision ...
CD Genomics, a global leader in genomics solutions, proudly announces the unveiling of its cutting-edge Full-Length 16S/18S/ITS Amplicon Sequencing service, designed to meet the comprehensive sequencing requirements of researchers in the fields of microbiology and mycology. This pioneering service represents a significant leap forward in genomics and offers an array of features aimed at ...
CD Genomics, an excellent leader in genomics and bioinformatics, has unveiled a groundbreaking leap forward in TCR-Seq technology, poised to revolutionize immune repertoire profiling. With an unwavering commitment to innovation and precision, CD Genomics continues to redefine the genomics research landscape. TCR-Seq, short for T Cell Receptor Sequencing, is an instrumental tool that enables ...
CD Genomics, a prominent leader in the genomics and transcriptomics arena, proudly unveils its latest innovation, the Degradome Sequencing service. This technology promises to revolutionize the field of transcriptomics research, offering researchers an unprecedented window into RNA degradation patterns and elevating our comprehension of gene regulation and expression. RNA degradation is a ...
CD Genomics, a trailblazing genomics and bioinformatics services provider, is delighted to announce the launch of the Long Amplicon Analysis (LAA) service, a mature genomic research method that promises to revolutionize the field. With LAA, scientists can now explore intricate genomic landscapes, facilitating groundbreaking discoveries and advancements in various branches of genomics. Long ...
SeqOne Genomics, provider of nextgeneration genomic analysis solutions for personalized medicine, announces the appointment of Hervé Pouzoullic as Chief Commercial Officer (CCO). He will lead the commercial development of the company to accelerate its growth and strengthen its international presence. Hervé has more than 25 years of experience in sales, business development and ...
BC Platforms (BCP), a global leader in healthcare data management and analytics, today announced that, together with Finland’s Euformatics and Hungary’s Oncompass Medicine, the BCP-led partnership has now successfully been awarded contract for the second phase of developing standardized oncology workflows for a buyer consortium of seven leading central European hospitals*, represented ...
Cellworks Group Inc. a leader in Precision Drug Development and Personalized Therapy Biosimulation, today announced results from a Cellworks biosimulation pilot study, which examined the impact of mismatch repair deficiency (MRD) on survival of temozolomide (TMZ)-treated patients with MGMT methylated (m-MGMT) glioblastoma (GBM). The biosimulation study validated that TMZ does not trigger ...
The Bioinformatics-Analysis, a subdivision of CD Genomics, provides reliable next-generation and third-generation high-throughput sequencing data analysis, comprehensive technology services, database construction, and other related data analysis services. CD Genomics provides metatranscriptome sequencing data analysis service using bioinformatics analysis platform, which can comprehensively ...